Gética 2020

[ F I T C á n c e r - 6 ] 37 33. Voorwerk L, Slagter M, Horlings HM, et al. Immune in- duction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med 2019;25(6):920-8. 34. Pilié PG, Gay CM, Byers LA, et al. PARP Inhibitors: Extend- ing Benefit Beyond BRCA -Mutant Cancers. Clinical Cancer Research 2019;25(13):3759-71. Disponible en: http:// clincancerres.aacrjournals.org/lookup/doi/10.1158/1078- 0432.CCR-18-0968 35. Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-Label Clinical Trial of Niraparib Combined with Pembrolizum- ab for Treatment of Advanced or Metastatic Triple-Neg- ative Breast Cancer. JAMA Oncol 2019;5(8):1132-40. Di- sponible en: http://oncology.jamanetwork.com/article. aspx?doi=10.1001/jamaoncol.2019.1029 36. Domchek S, Postel-Vinay S, Im S-A, et al. 1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIO- LA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Ann Oncol 2019;30(Suppl.5). Disponible en: https://academic.oup.com/annonc/article/30/Supple- ment_5/mdz253.017/5576835 37. Han HS, Alemany CA, Brown-Glaberman UA, et al. SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastat- ic triple-negative breast cancer. JCO 2019;37(Sup- pl.15):TPS1110-TPS1110. 38. Adams S, Gatti-Mays ME, Kalinsky K, et al. Current Land- scape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol 2019;5(8):1205. 39. Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemother- apy (chemo) vs placebo (pbo) + chemo as neoadju- vant treatment, followed by pembro vs pbo as adju- vant treatment for early triple-negative breast cancer (TNBC). Ann Oncol 2019;30:v853-4. Logros y posicionamiento terapéutico de la inmunoterapia en cáncer de mama